J Clin Gastroenterol 2003;36(5):458–461.

© 2003 Lippincott Williams & Wilkins, Inc.

AUTHOR INDEX FOR VOLUME 36

Abbott SL. See Levy V
Abreu MT
—Yang H: Defining Subtypes of Crohn's Disease Patients: The Ground Work for Translational Research in Inflammatory Bowel Disease, 3
Abuksis G. See Niv Y
Accetta MG. See Basile G
Agarwal N
—Pitchumoni CS: Management of Pain in Chronic Pancreatitis: Medical or Surgical, 98
Ahdab HA. See Özdoğan O
Ahdab YA. See Özdoğan O
Ahmed A. See Yen T
Aiello A. See Daniele B
Akahane M. See Gunji T
Al Kharrat H
—Carcinoid Crisis Induced by External Manipulation of Liver Metastasis, 87
Albuquerque MFPM. See Melo ETC
Almeida JR. See Melo ETC
Anagnostopoulos GK
—Kostopoulos P, Margantinis G, Tsiakos S, Arvanitidis D: Omeprazole Plus Azithromycin and Either Amoxicillin or Tinidazole for Eradication of *Helicobacter pylori* Infection, 325
Ando T. See Takeuchi K
Andreana A. See Daniele B
Anjiki H. See Yamamoto T
Ansari R. See Merat S
Antonelli G. See Papi C
Aragona G. See Di Mario F
Aramaki M. See Matsumoto T
Archimandritis AJ
—The Incidence of *Helicobacter pylori* Is not Increased in Obese People, but the Risk of Duodenal Ulcer Is Higher in *H. pylori*–Positive People of High Obesity, 184
Ardizzone S. See Bargiggia S
Armuzzi A. See Candelli M
Arnold GL. See Mardini HE
Arrese M. See Riquelme AJ
Arvanitidis D. See Anagnostopoulos GK
Ashur Y. See Menachem Y
Avidan B. See Fidder HH

Baiocco PJ. See Zlatanic J
Baldassarri A. See Piodi LP
Bansal R
—Nostrant TT, Scheiman JM, Koshy S, Barnett JL, Elta GH, Chey WD: Intrasphincteric Botulinum Toxin Versus Pneumatic Balloon Dilation For Treatment of Primary Achalasia, 209
Bar-Meir S. See Fidder HH
Barakat B. See Pezzilli R
Bardella M. See Piodi LP
Bargiggia S
—Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, Todaro I, Greco S, Manzionna G, Porro GB: Sonographic Prevalence of Liver Steatosis and Biliary Tract Stones in Patients with Inflammatory Bowel Disease: Study of 511 Subjects at a Single Center, 417
Barnes DS. See Younossi ZM
Barnett JL. See Bansal R
Baron J. See Sørensen HT
Basile G
—Villari D, Gangemi S, Ferrara T, Accetta MG, Nicita-Mauro V: Candesartan Cilexetil-Induced Severe Hepatotoxicity, 273
Bell BP. See Navarro VJ
Beltrandi E. See Pezzilli R
Bhattacharya R
—Shuhart MC: Hepatitis C and Alcohol: Interactions, Outcomes, and Implications, 242
Bin-Sagheer S. See McIlwain L
Boehm SA
—Synchronous Nonfunctioning Neuroendocrine Carcinoma of the Pancreas and Appendix, 452
Bonkovsky HL
—Optimal Management of Nonalcoholic Fatty Liver/Steatohepatitis, 193
Boyce HW. See West AB
Boyce HW
—Barrett Esophagus: Endoscopic Findings and What to Biopsy, S6
Bozkaya H. See Serinoz E
Brandimarte G. See Tursi A
Brown A
—Predicting Severity in Acute Pancreatitis: In Search of a Perfect Marker, 195
Brown RD. See Chandrashekar L
Brown WH
—Chey WD, Elta GH: Number of Responses on a Review of Systems Questionnaire Predicts the Diagnosis of Functional Gastrointestinal Disorders, 222
Bruno CJ. See Cai Q
Byrne MF
—Association of *Clostridium difficile* Infection With Collagenous Colitis, 285

Cai Q
—Bruno CJ, Hagedorn CH, Desbiens NA: Temporal Trends Over Ten Years in Formal Inpatient Gastroenterology Consultations at an Inner City Hospital, 34
Calvo MA. See Riquelme AJ
Cameron JL. See Thuluvath PJ
Cammarota G
—Elia F, Cianci R, Galli J, Paolillo N, Montalto M, Gasbarrini G: Worsening of Gastroesophageal Reflux Symptoms in Professional Singers During Performances, 403
Canataroglu A. See Gumurdulu Y
Candelli M
—Nista EC, Nestola M, Armuzzi A, Silveri NG, Gasbarrini G, Gasbarrini A: *Saccharomyces cerevisiae*–Associated Diarrhea in an Immunocompetent Patient With Ulcerative Colitis, 39
Capuano G. See Daniele B
Capurso L. See Papi C
Carey WD. See Younossi ZM
Carter JD. See McIlwain L
Carvalho ATP
—Elia CCS, de Souza HSP, Elias PRP, Pontes EL, Lukashok HP, de Freitas FCD, e Silva JRL: Immunohistochemical Study of Intestinal Eosinophils in Inflammatory Bowel Disease, 120
Castellote J. See Sese E
Cavestro GM. See Di Mario F
Cellerino P. See Morandi E
Cesana BM. See Piodi LP
Chacko A. See Mukhopadhya A
Chandrashekar L
—Brown RD, Venu RP: Management of Dieulafoy's Lesion in the Endoscopic Era, 294
Chatzicostas C
—Roussomoustakaki M, Vardas E, Romanos J, Kouroumalis EA: Balthazar Computed Tomography Severity Index Is Superior to Ranson Criteria and APACHE II and III Scoring Systems in Predicting Acute Pancreatitis Outcome, 253
Chen C-N. See Lee W-J
Chen Y-C
—Yeh C-N, Tseng J-H: Symptomatic Adult Annular Pancreas, 446
Chey WD. See Bansal R
Chey WD. See Brown WH
Chiba T
—Yokosuka O, Kojima H, Fukai K, Imazeki F, Saisho H, Nishimura M, Saito Y: Chronic Graft-Versus-Host Disease Complicated by Acute Hepatitis B, 179
Chowers Y. See Fidder HH
Chrysohoou C. See Stefanadis C
Cianci R. See Cammarota G
Cinar K. See Serinoz E
Çolakoglu S. See Gumurdulu Y
Corinaldesi R. See Pezzilli R
Corsi F. See Morandi E
Cotler SJ
—Morrissey MJ, Wiley TE, Layden TJ, Jensen DM: A Pilot Study of the Combination of Cyclosporin A and Interferon Alfacon-1 for the Treatment of Hepatitis C in Previous Nonresponder Patients, 352
Craig RM
—Borderline Enteropathies, 6
Crawford JM. See Landi K

Dabney-Smith K
—Severe Esophagitis Healed in Less Than a Week With Intravenous Pantoprazole, 78
Dal Bò N. See Di Mario F
Dane F. See Özdoğan O
Daniele B
—De Sio I, Izzo F, Capuano G, Andreana A, Mazzanti R, Aiello A, Vallone P, Fiore F, Gaeta GB, Perrone F, Pignata S, Gallo C: Hepatic Resection and Percutaneous Ethanol Injection as Treatments of Small Hepatocellular Carcinoma: A Cancer of the Liver Italian Program (CLIP 08) Retrospective Case–Control Study, 63
—Rosati G, Tambaro R, Ottaiano A, De Maio E, Pignata S, Iaffaioli RV, Rossi A, Manzione L, Gallo C, Perrone F: First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients: A Phase II Study, 228
Davis K. See Nair P
de Freitas FCD. See Carvalho ATP
De Maio E. See Daniele B
De Sio I. See Daniele B
de Souza HSP. See Carvalho ATP
del Olmo JA. See Serra MA
Demirtürk L. See Yazgan Y
Depix MS. See Riquelme AJ
Desbiens NA. See Cai Q
Di Mario F
—Aragona G, Dal Bò N, Ingegnoli A, Cavestro GM, Moussa AM, Iori V, Leandro G, Pilotto A, Franzè A: Use of Lactoferrin for *Helicobacter pylori* Eradication, 396
Dickey W. See Mitchell RMS
Dimitroulopoulos D. See Stefanadis C
Dutta S. See Nair P

e Silva JRL. See Carvalho ATP
Easley K. See Younossi ZM
Elia CCS. See Carvalho ATP
Elia F. See Cammarota G
Elias PRP. See Carvalho ATP
Elli M. See Bargiggia S
Elta GH. See Bansal R
Elta GH. See Brown WH
Ercan M. See Yazgan Y
Erden E. See Serinoz E
Ernst E
—Complementary Medicine in Gastroenterology: More Than a Fad?, 453
Escudero A. See Serra MA

Farahvash MJ. See Merat S
Ferrara T. See Basile G
Fickling WE
—Wallace MB: Endoscopic Ultrasound and Upper Gastrointestinal Disorders, 103

J Clin Gastroenterol 2003;36(5):458–461.

© 2003 Lippincott Williams & Wilkins, Inc.

AUTHOR INDEX FOR VOLUME 36

Abbott SL. See Levy V
Abreu MT
—Yang H: Defining Subtypes of Crohn's Disease Patients: The Ground Work for Translational Research in Inflammatory Bowel Disease, 3
Abuksis G. See Niv Y
Accetta MG. See Basile G
Agarwal N
—Pitchumoni CS: Management of Pain in Chronic Pancreatitis: Medical or Surgical, 98
Ahdab HA. See Özdoğan O
Ahdab YA. See Özdoğan O
Ahmed A. See Yen T
Aiello A. See Daniele B
Akahane M. See Gunji T
Al Kharrat H
—Carcinoid Crisis Induced by External Manipulation of Liver Metastasis, 87
Albuquerque MFPM. See Melo ETC
Almeida JR. See Melo ETC
Anagnostopoulos GK
—Kostopoulos P, Margantinis G, Tsiakos S, Arvanitidis D: Omeprazole Plus Azithromycin and Either Amoxicillin or Tinidazole for Eradication of *Helicobacter pylori* Infection, 325
Ando T. See Takeuchi K
Andreana A. See Daniele B
Anjiki H. See Yamamoto T
Ansari R. See Merat S
Antonelli G. See Papi C
Aragona G. See Di Mario F
Aramaki M. See Matsumoto T
Archimandritis AJ
—The Incidence of *Helicobacter pylori* Is not Increased in Obese People, but the Risk of Duodenal Ulcer Is Higher in *H. pylori*–Positive People of High Obesity, 184
Ardizzone S. See Bargiggia S
Armuzzi A. See Candelli M
Arnold GL. See Mardini HE
Arrese M. See Riquelme AJ
Arvanitidis D. See Anagnostopoulos GK
Ashur Y. See Menachem Y
Avidan B. See Fidder HH

Baiocco PJ. See Zlatanic J
Baldassarri A. See Piodi LP
Bansal R
—Nostrant TT, Scheiman JM, Koshy S, Barnett JL, Elta GH, Chey WD: Intrasphincteric Botulinum Toxin Versus Pneumatic Balloon Dilation For Treatment of Primary Achalasia, 209
Bar-Meir S. See Fidder HH
Barakat B. See Pezzilli R
Bardella M. See Piodi LP
Bargiggia S
—Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, Todaro I, Greco S, Manzionna G, Porro GB: Sonographic Prevalence of Liver Steatosis and Biliary Tract Stones in Patients with Inflammatory Bowel Disease: Study of 511 Subjects at a Single Center, 417
Barnes DS. See Younossi ZM
Barnett JL. See Bansal R
Baron J. See Sørensen HT
Basile G
—Villari D, Gangemi S, Ferrara T, Accetta MG, Nicita-Mauro V: Candesartan Cilexetil-Induced Severe Hepatotoxicity, 273
Bell BP. See Navarro VJ
Beltrandi E. See Pezzilli R
Bhattacharya R
—Shuhart MC: Hepatitis C and Alcohol: Interactions, Outcomes, and Implications, 242
Bin-Sagheer S. See McIlwain L
Boehm SA
—Synchronous Nonfunctioning Neuroendocrine Carcinoma of the Pancreas and Appendix, 452
Bonkovsky HL
—Optimal Management of Nonalcoholic Fatty Liver/Steatohepatitis, 193
Boyce HW. See West AB
Boyce HW
—Barrett Esophagus: Endoscopic Findings and What to Biopsy, S6
Bozkaya H. See Serinoz E
Brandimarte G. See Tursi A
Brown A
—Predicting Severity in Acute Pancreatitis: In Search of a Perfect Marker, 195
Brown RD. See Chandrashekar L
Brown WH
—Chey WD, Elta GH: Number of Responses on a Review of Systems Questionnaire Predicts the Diagnosis of Functional Gastrointestinal Disorders, 222
Bruno CJ. See Cai Q
Byrne MF
—Association of *Clostridium difficile* Infection With Collagenous Colitis, 285

Cai Q
—Bruno CJ, Hagedorn CH, Desbiens NA: Temporal Trends Over Ten Years in Formal Inpatient Gastroenterology Consultations at an Inner City Hospital, 34
Calvo MA. See Riquelme AJ
Cameron JL. See Thuluvath PJ
Cammarota G
—Elia F, Cianci R, Galli J, Paolillo N, Montalto M, Gasbarrini G: Worsening of Gastroesophageal Reflux Symptoms in Professional Singers During Performances, 403
Canataroglu A. See Gumurdulu Y
Candelli M
—Nista EC, Nestola M, Armuzzi A, Silveri NG, Gasbarrini G, Gasbarrini A: *Saccharomyces cerevisiae*–Associated Diarrhea in an Immunocompetent Patient With Ulcerative Colitis, 39
Capuano G. See Daniele B
Capurso L. See Papi C
Carey WD. See Younossi ZM
Carter JD. See McIlwain L
Carvalho ATP
—Elia CCS, de Souza HSP, Elias PRP, Pontes EL, Lukashok HP, de Freitas FCD, e Silva JRL: Immunohistochemical Study of Intestinal Eosinophils in Inflammatory Bowel Disease, 120
Castellote J. See Sese E
Cavestro GM. See Di Mario F
Cellerino P. See Morandi E
Cesana BM. See Piodi LP
Chacko A. See Mukhopadhya A
Chandrashekar L
—Brown RD, Venu RP: Management of Dieulafoy's Lesion in the Endoscopic Era, 294
Chatzicostas C
—Roussomoustakaki M, Vardas E, Romanos J, Kouroumalis EA: Balthazar Computed Tomography Severity Index Is Superior to Ranson Criteria and APACHE II and III Scoring Systems in Predicting Acute Pancreatitis Outcome, 253
Chen C-N. See Lee W-J
Chen Y-C
—Yeh C-N, Tseng J-H: Symptomatic Adult Annular Pancreas, 446
Chey WD. See Bansal R
Chey WD. See Brown WH
Chiba T
—Yokosuka O, Kojima H, Fukai K, Imazeki F, Saisho H, Nishimura M, Saito Y: Chronic Graft-Versus-Host Disease Complicated by Acute Hepatitis B, 179
Chowers Y. See Fidder HH
Chrysohoou C. See Stefanadis C
Cianci R. See Cammarota G
Cinar K. See Serinoz E
Çolakoglu S. See Gumurdulu Y
Corinaldesi R. See Pezzilli R
Corsi F. See Morandi E
Cotler SJ
—Morrissey MJ, Wiley TE, Layden TJ, Jensen DM: A Pilot Study of the Combination of Cyclosporin A and Interferon Alfacon-1 for the Treatment of Hepatitis C in Previous Nonresponder Patients, 352
Craig RM
—Borderline Enteropathies, 6
Crawford JM. See Landi K

Dabney-Smith K
—Severe Esophagitis Healed in Less Than a Week With Intravenous Pantoprazole, 78
Dal Bò N. See Di Mario F
Dane F. See Özdoğan O
Daniele B
—De Sio I, Izzo F, Capuano G, Andreana A, Mazzanti R, Aiello A, Vallone P, Fiore F, Gaeta GB, Perrone F, Pignata S, Gallo C: Hepatic Resection and Percutaneous Ethanol Injection as Treatments of Small Hepatocellular Carcinoma: A Cancer of the Liver Italian Program (CLIP 08) Retrospective Case–Control Study, 63
—Rosati G, Tambaro R, Ottaiano A, De Maio E, Pignata S, Iaffaioli RV, Rossi A, Manzione L, Gallo C, Perrone F: First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients: A Phase II Study, 228
Davis K. See Nair P
de Freitas FCD. See Carvalho ATP
De Maio E. See Daniele B
De Sio I. See Daniele B
de Souza HSP. See Carvalho ATP
del Olmo JA. See Serra MA
Demirtürk L. See Yazgan Y
Depix MS. See Riquelme AJ
Desbiens NA. See Cai Q
Di Mario F
—Aragona G, Dal Bò N, Ingegnoli A, Cavestro GM, Moussa AM, Iori V, Leandro G, Pilotto A, Franzè A: Use of Lactoferrin for *Helicobacter pylori* Eradication, 396
Dickey W. See Mitchell RMS
Dimitroulopoulos D. See Stefanadis C
Dutta S. See Nair P

e Silva JRL. See Carvalho ATP
Easley K. See Younossi ZM
Elia CCS. See Carvalho ATP
Elia F. See Cammarota G
Elias PRP. See Carvalho ATP
Elli M. See Bargiggia S
Elta GH. See Bansal R
Elta GH. See Brown WH
Ercan M. See Yazgan Y
Erden E. See Serinoz E
Ernst E
—Complementary Medicine in Gastroenterology: More Than a Fad?, 453
Escudero A. See Serra MA

Farahvash MJ. See Merat S
Ferrara T. See Basile G
Fickling WE
—Wallace MB: Endoscopic Ultrasound and Upper Gastrointestinal Disorders, 103

Fidder HH
—Avidan B, Lahav M, Bar-Meir S, Chowers Y: Clinical and Demographic Characterization of Jewish Crohn's Disease Patients in Israel, 8
Fiore F. See Daniele B
Fisher R. See West AB
Floch MH
—*Saccharomyces*: Is It a Probiotic or a Pathogen and What Is the Significance of an Elevated Anti–*S. cerevisiae* Antibody?, 5
—Hepatitis B and C: Management and Treatment, *by Thierry Poynard*, 89
—Living With Hepatitis C: A Survivor's Guide, *by Gregory T. Everson and Hedy Weinberg*, 89
—Practical Gastroenterology, *by Stuart Bloom*, 89
—Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management, 7th Edition, Vols. 1 and 2, *by Mark Feldman, Lawrence S. Friedman, and Marvin H. Sleisenger*, 189
—Infections of the Gastrointestinal Tract, 2nd Edition, *by Martin J. Blaser, Phillip D. Smith, Jonathan I. Ravdin, et al., eds.*, 189
—Therapeutic Gastrointestinal Endoscopy, *by David Westaby and Martin Lombard*, 189
—Gastrointestinal Immunology, *by Alajos Pár, István Rácz, and Gyula Mózsik*, 375
—Hepatology: A Textbook of Liver Diseases, 4th Edition, *by David Zakim and Thomas D. Boyer*, 375
—West AB, Nair S: Defining the Pathologic and Clinical Significance of Dysplasia and Metaplasia in the Gastrointestinal Tract, S1
Franzè A. See Di Mario F
Freeman HJ
—Collagenous Sprue Associated With an Extensive T-cell Lymphoma, 144
Frucht H. See Larghi A
Fujimoto K. See Matsunaga K
Fujino T. See Yamada T
Fukai K. See Chiba T

Gaeta GB. See Daniele B
Galli J. See Cammarota G
Gallo C. See Daniele B
Gangemi S. See Basile G
García P. See Riquelme AJ
Gasbarrini A. See Candelli M
Gasbarrini G. See Cammarota G
Gasbarrini G. See Candelli M
Genta R. See West AB
Genta RM
—The Gastritis Connection: Prevention and Early Detection of Gastric Neoplasms, S44
Gili L. See Papi C
Giorgetti GM. See Tursi A
Goldblum J. See West AB
Goldblum JR
—The Histologic Diagnosis of Dysplasia, Dysplasia-Associated Lesion or Mass, and Adenoma: A Pathologist's Perspective, S63
Gramlich T. See Younossi ZM
Granderath FA
—Characterization of Long-Term Outcomes After Toupet Fundoplication, 182
Granot E. See Shuval-Sudai O
Grassi C. See Morandi E
Greco S. See Bargiggia S
Gumurdulu D. See Gumurdulu Y
Gumurdulu Y
—Yapar Z, Canataroglu A, Serin E, Gumurdulu D, Kibar M, Çolakoglu S: Gastric Emptying Time and the Effect of Cisapride in Cirrhotic Patients With Autonomic Neuropathy, 175
Gunji T
—Kawauchi N, Akahane M, Watanabe K, Kanamori H, Ohnishi S: Treatment of Unresectable Hepatocellular Carcinoma Less Than 2 Centimeters by Transcatheter Arterial Chemoembolization With Autologous Blood Clot, 347
Gürbüz AK
—Does High Albumin Gradient Ascites Accompany Tuberculous Peritonitis?, 82
Guzmán AM. See Riquelme AJ

Hagedorn CH. See Cai Q
Hall CH Jr.
—Shamma M: Primary Intestinal Lymphoma Complicating Crohn's Disease, 332
Hara M. See Matsunaga K
Hara T. See Takeuchi K
Hart AL
—Stagg AJ, Kamm MA: Use of Probiotics in the Treatment of Inflammatory Bowel Disease, 111
Hasegawa M. See Kitamoto Y
Hattori K. See Yamamoto T
Helper DJ. See Weston BR
Himeno Y. See Matsumoto T
Hirai S. See Yamada T
Hirano S. See Matsumoto T
Hodnick S. See Younossi ZM
Hong R-L. See Lee W-J
Hormazdi M. See Merat S
Houghton J. See Zivny J
Hozyasz KK
—Celiac Disease Presenting During Puerperium, 81
Huang M-T. See Lee W-J

Iaffaioli RV. See Daniele B
Ilan Y. See Menachem Y
Imazeki F. See Chiba T
İmeryüz N. See Özdoğan O
Imperio D. See Thuluvath PJ
Ingegnoli A. See Di Mario F
Iori V. See Di Mario F
Ipekci SH
—The Fluctuation of Serum Levels of Aminotransferase in Patients With Nonalcoholic Steatohepatitis, 371
Ishii T. See Yamamoto T
Ishikawa H. See Kitamoto Y
Israelski D. See Levy V
Itzkowitz S. See West AB
Itzkowitz S
—Colon Carcinogenesis in Inflammatory Bowel Disease: Applying Molecular Genetics to Clinical Practice, S70
Iwakiri R. See Matsunaga K
Izzo F. See Daniele B

Jang TJ
—Kim NI, Yang CH: Carditis Is Associated With *Helicobacter pylori*–Induced Gastritis and Not Reflux Esophagitis, 26
Jansen JBMJ. See Laheij RJF
Jensen DM. See Cotler SJ
Jepsen P. See Sørensen HT

Kamm MA. See Hart AL
Kanamori H. See Gunji T
Kansu A. See Serinoz E
Kapadia C. See West AB
Kapadia CR
—Gastric Atrophy, Metaplasia, and Dysplasia: A Clinical Perspective, S29
Karoutsos K. See Stefanadis C
Kawano K. See Matsumoto T
Kawauchi N. See Gunji T
Keeffe EB. See Yen T
Khatibian M. See Merat S
Kibar M. See Gumurdulu Y
Kim DJ
—*Klebsiella* Liver Abscess, 186
Kim KH. See Ryu JK
Kim KH. See Zivny J
Kim NI. See Jang TJ
Kim PS. See Zlatanic J
Kitamoto Y
—Hasegawa M, Ishikawa H, Saito J-i, Yamakawa M, Kojima M, Nakano T: Mucosa-Associated Lymphoid Tissue Lymphoma of the Esophagus: A Case Report, 414
Kitano S. See Matsumoto T
Kiykim A
—Successful Treatment of Acute Hepatic Injury Caused by Paracetamol Intoxication in a Late-Referral Patient by *N*-Acetylcysteine, 372
Kojima H. See Chiba T
Kojima M. See Kitamoto Y
Korelitz BI. See Zlatanic J
Kori T. See Takeuchi K
Koshy S. See Bansal R
Kostopoulos P. See Anagnostopoulos GK
Kouroumalis EA. See Chatzicostas C
Kuwano H. See Takeuchi K
Kuyama Y. See Yamamoto T

Labarca JA. See Riquelme AJ
Lagerholm S. See Nair P
Lahav M. See Fidder HH
Laheij RJF
—van Rossum LGM, Verbeek ALM, Jansen JBMJ: *Helicobacter pylori* Infection Treatment of Nonulcer Dyspepsia: An Analysis of Meta-Analyses, 315
Lai I-R. See Lee W-J
Landi K
—Sinard J, Crawford JM, Topazian M: Cholesterol Crystal Morphology in Acalculous Gallbladder Disease, 364
Lankarani KB
—Use of Mycophenolate Mofetil in the Treatment of Primary Sclerosing Cholangitis, 86
Larghi A
—Leffler D, Frucht H, Rubin M, Semrad CE, Lefkowitch JH, Worman HJ: Hepatitis B Virus Reactivation After Kidney Transplantation and New Onset Lymphoma, 276
Larson AM
—Liver Disease in Hereditary Hemorrhagic Telangiectasia, 149
Lauwers G. See West AB
Lauwers GY
—Defining the Pathologic Diagnosis of Metaplasia, Atrophy, Dysplasia, and Gastric Adenocarcinoma, S37
Layden TJ. See Cotler SJ
Leandro G. See Di Mario F
Lee P-H. See Lee W-J
Lee SD. See Rulyak SJ
Lee W-J
—Hong R-L, Lai I-R, Chen C-N, Lee P-H, Huang M-T: Clinicopathologic Characteristics and Prognoses of Gastric Cancer in Patients With a Positive Familial History of Cancer, 30
Leffler D. See Larghi A
Lefkowitch JH. See Larghi A
Levy V
—Reed C, Abbott SL, Israelski D: *Escherichia coli* Myonecrosis in Alcoholic Cirrhosis, 443
Lewis M
—Grace Helen Elta, M.D., 1
—John H. Bond, M.D., 289
Lidar M
—Sclerosing Cholangitis Associated With Systemic Sarcoidosis, 84
Lieber CS
—Hepatitis C and Alcohol, 100
Liebermann BY. See Younossi ZM
Lobel EZ
—Red Man Syndrome and Infliximab, 186
Loftus E. See West AB
Loftus EV Jr.
—Does Monitoring Prevent Cancer in Inflammatory Bowel Disease?, S79
Lopes EPA. See Melo ETC
Lukashok HP. See Carvalho ATP

Ma S. See Nair P
Maconi G. See Bargiggia S

Mahl TC
—Metronidazole and Mental Confusion, 373
Malayeri M. See Nair P
Maldini M. See Pezzilli R
Malekzadeh R. See Merat S
Manzione L. See Daniele B
Manzionna G. See Bargiggia S
Mardini HE
—Arnold GL: Utility of Measuring 6-Methylmercaptopurine and 6-Thioguanine Nucleotide Levels in Managing Inflammatory Bowel Disease Patients Treated With 6-Mercaptopurine in a Clinical Practice Setting, 390
Margantinis G. See Anagnostopoulos GK
Massara PP. See Morandi E
Massoud OI
—Yousef WI, Mullen KD: Hemoglobinuria With Ribavirin Treatment, 367
Mastropasqua E
—*Giardia* Duodenalis: A Confounding Factor for the Diagnosis of Celiac Disease, 185
Matsumaru K
—A Renal Allograft Recipient With Viral-Burden, Steatoviral, and Fibroviral Hepatitis B Who Achieved Remission With Lamivudine, 187
Matsumoto A
—How Should We Improve the Clinical Course of Patients With Gastric Varices?, 372
Matsumoto T
—Aramaki M, Yada K, Hirano S, Himeno Y, Shibata K, Kawano K, Kitano S: Optimal Management of the Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas, 261
Matsunaga K
—Iwakiri R, Hara M, Sakata H, Ogusu T, Shimoda R, Oda K, Utsumi H, Yamamoto K, Fujimoto K: Endoscopic Injection Sclerotherapy for Esophageal Varices in Cirrhotic Patients With Hepatocellular Carcinoma: Risk Factors for Survival, 68
Mazzanti R. See Daniele B
McCullough AC. See Younossi ZM
McIlwain L
—Carter JD, Bin-Sagheer S, Vasey FB, Nord J: Hypersensitivity Vasculitis with Leukocytoclastic Vasculitis Secondary to Infliximab, 411
McQuaid KR
—Eradication of *Helicobacter pylori* in Nonulcer Dyspepsia: How Much Analysis Do We Need?, 291
Mellemkjær L. See Sørensen HT
Melo ETC
—Lopes EPA, Almeida JR, Albuquerque MFPM, Moura IMF: Seroprevalence of *Helicobacter pylori* Antibodies in Medical Students and Residents in Recife, Brazil, 134
Menachem Y
—Safadi R, Ashur Y, Ilan Y: Malignancy After Liver Transplantation in Patients With Premalignant Conditions, 436
Merat S
—Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, Farahvash MJ, Ansari R, Sotoudehmanesh R, Khatibian M: Probucol in the Treatment of Nonalcoholic Steatohepatitis: An Open-Labeled Study, 266
Meyer JM
—Use of Lactoferrin for *Helicobacter pylori* Eradication, 384
Migliori M. See Pezzilli R
Mikaeli J. See Merat S
Mitchell RMS
—O'Connor F, Dickey W: Endoscopic Retrograde Cholangiopancreatography Is Safe and Effective in Patients 90 Years of Age and Older, 72
Miwa H. See Yamada T
Mohan V
—Premalatha G, Pitchumoni CS: Tropical Chronic Pancreatitis: An Update, 337
Molteni P. See Bargiggia S
Montalto M. See Cammarota G
Morandi E
—Grassi C, Cellerino P, Massara PP, Corsi F, Trabucchi E: Verocytotoxin-Producing *Escherichia coli* EH 0157:H7 Colitis, 44
Morrissey MJ. See Cotler SJ
Morselli-Labate AM. See Pezzilli R
Moses BV. See Mukhopadhya A
Moura IMF. See Melo ETC
Moussa AM. See Di Mario F
Mukhopadhya A
—Samal SC, Mukundan U, Patra S, Moses BV, Chacko A: Perianal Fistulae Caused by *Mycobacterium fortuitum*, 147
Mukundan U. See Mukhopadhya A
Mullen KD. See Massoud OI
Mullen KD. See Younossi ZM
Mumtaz R
—Shaukat M, Ramirez FC: Outcomes of Endoscopic Treatment of Gastroduodenal Dieulafoy's Lesion With Rubber Band Ligation and Thermal/Injection Therapy, 310

Nair P. See West AB
Nair P
—Lagerholm S, Dutta S, Shami S, Davis K, Ma S, Malayeri M: Coprocytobiology: On the Nature of Cellular Elements from Stools in the Pathophysiology of Colonic Disease, S84
Nair S. See Floch MH
Nair S. See Thuluvath PJ
Nakano T. See Kitamoto Y
Naserimoghadam S. See Merat S
Navarro VJ
—St. Louis TE, Bell BP: Identification of Patients with Hepatitis C Virus Infection in New Haven County Primary Care Practices, 431
Nestola M. See Candelli M
Nicita-Mauro V. See Basile G
Nishimura M. See Chiba T
Nista EC. See Candelli M
Niv Y
—Abuksis G: Survey of the Opinions, Knowledge and Practices of Surgeons and Internists Regarding *Helicobacter pylori* Test-and-Treat Policy, 139
—Family History of Gastric Cancer: Should We Test and Treat for *Helicobacter pylori?*, 204
Nord J. See McIlwain L
Nostrant TT. See Bansal R

O'Connor F. See Mitchell RMS
Oda K. See Matsunaga K
Ogusu T. See Matsunaga K
Ohnishi S. See Gunji T
Ohno Y. See Takeuchi K
Okai T
—Erythematous Maculopapular Eruption due to Ribavirin Administration in a Patient With Chronic Hepatitis C, 283
Olsen JH. See Sørensen HT
Ottaiano A. See Daniele B
Özdoğan O
—Ratip S, Ahdab YA, Dane F, Ahdab HA, İmeryüz N, Tözün N: Causes and Risk Factors for Liver Injury Following Bone Marrow Transplantation, 421
Özel AM. See Yazgan Y

Panagiotakos DB. See Stefanadis C
Panagopoulos G. See Zlatanic J
Paolillo N. See Cammarota G
Papadakis KA
—Optimizing the Therapeutic Potential of Azathioprine/6-Mercaptopurine in the Treatment of Inflammatory Bowel Disease, 379
Papadimitriou C. See Stefanadis C
Papi C
—Gili L, Tarquini M, Antonelli G, Capurso L: Infliximab for Severe Recurrent Crohn's Disease Presenting With Massive Gastrointestinal Hemorrhage, 238
Paraskevas E. See Stefanadis C
Parente F. See Bargiggia S
Patra S. See Mukhopadhya A
Pérez C. See Riquelme AJ
Perrone F. See Daniele B
Petraki K. See Stefanadis C
Pezzilli R
—Maldini M, Morselli-Labate AM, Barakat B, Romboli E, Beltrandi E, Migliori M, Tomassetti P, Corinaldesi R: Early Activation of Peripheral Lymphocytes in Human Acute Pancreatitis, 360
Pignata S. See Daniele B
Pilotto A. See Di Mario F
Piodi LP
—Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M: Possible Protective Effect of 5-Aminosalicylic Acid on *Helicobacter pylori* Infection in Patients With Inflammatory Bowel Disease, 22
Pitchumoni CS. See Agarwal N
Pitchumoni CS. See Mohan V
Pitchumoni CS. See Yadav D
Pitsavos C. See Stefanadis C
Pontes EL. See Carvalho ATP
Porro GB. See Bargiggia S
Premalatha G. See Mohan V
Proctor D. See West AB

Quatrini M. See Piodi LP

Rajapakse R. See Zlatanic J
Ramirez FC. See Mumtaz R
Ratip S. See Özdoğan O
Reed C. See Levy V
Rex DK. See Weston BR
Riquelme AJ
—Calvo MA, Guzmán AM, Depix MS, García P, Pérez C, Arrese M, Labarca JA: *Saccharomyces cerevisiae* Fungemia After *Saccharomyces boulardii* Treatment in Immunocompromised Patients, 41
Robert M. See West AB
Robert ME
—Defining Dysplasia in Barrett Esophagus, S19
Rocchia C. See Piodi LP
Rodrigo JM. See Serra MA
Rodríguez F. See Serra MA
Rodríguez-Fariñas E. See Sese E
Romanos J. See Chatzicostas C
Romboli E. See Pezzilli R
Rosati G. See Daniele B
Rossi A. See Daniele B
Roussomoustakaki M. See Chatzicostas C
Rubin M. See Larghi A
Rubin SD. See Zlatanic J
Rulyak SJ
—Saunders MD, Lee SD: Hepatotoxicity Associated With 6-Thioguanine Therapy for Crohn's Disease, 234
Ryu JK
—Ryu KH, Kim KH: Clinical Features of Acute Acalculous Cholecystitis, 166
Ryu KH. See Ryu JK

Sabol DA
—Use of Stent Retrieval Rat Tooth Forceps for Percutaneous Endoscopic Gastrostomy/Jejunostomy Tube Placement, 80
Safadi R. See Menachem Y
Saisho H. See Chiba T
Saito J-i. See Kitamoto Y
Saito Y. See Chiba T
Saitoh M. See Yamamoto T
Sakata H. See Matsunaga K
Samal SC. See Mukhopadhya A
Samonakis DN
—Increased Incidence of Fungal Infections in Advanced Primary Biliary Cirrhosis, 369
Sanaka M. See Yamamoto T

Sanaka M
—The "Corrected" Half Emptying Time Is a Valueless Parameter in the 13C-Octanoic Acid Breath Test: Misuse of the Regression Analysis, 284
Sato N. See Yamada T
Saunders MD. See Rulyak SJ
Schattner M
—Enteral Nutritional Support of the Patient With Cancer: Route and Role, 297
Scheiman JM. See Bansal R
Schiff E
—Multiple Liver Abscesses After Dental Treatment, 369
Schleinitz N
—Autoimmune Thrombotic Thrombocytopenic Purpura: A Severe Complication of Inflammatory Bowel Disease, 83
Sekihara M. See Takeuchi K
Semrad CE. See Larghi A
Sepulveda AR
—Improvement of Gastric Atrophy After Cure of *Helicobacter pylori*, 382
Serin E. See Gumurdulu Y
Serinoz E
—Varli M, Erden E, Cinar K, Kansu A, Uzunalimoglu O, Yurdaydin C, Bozkaya H: Nuclear Localization of Hepatitis B Core Antigen and Its Relations to Liver Injury, Hepatocyte Proliferation, and Viral Load, 269
Serra MA
—Escudero A, Rodríguez F, del Olmo JA, Rodrigo JM: Effect of Hepatitis C Virus Infection and Abstinence From Alcohol on Survival in Patients With Alcoholic Cirrhosis, 170
Sese E
—Xiol X, Castellote J, Rodríguez-Fariñas E, Tremosa G: Low Complement Levels and Opsonic Activity in Hepatic Hydrothorax: Its Relationship With Spontaneous Bacterial Empyema, 75
Shami S. See Nair P
Shamma M. See Hall CH Jr.
Shaukat M. See Mumtaz R
Shibata K. See Matsumoto T
Shimoda R. See Matsunaga K
Shuhart MC. See Bhattacharya R
Shuval-Sudai O
—Granot E: An Association Between *Helicobacter pylori* Infection and Serum Vitamin B_{12} Levels in Healthy Adults, 130
Silveri NG. See Candelli M
Sinard J. See Landi K
Sohrabi MR. See Merat S
Sørensen HT
—Mellemkjær L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, Vilstrup H: Risk of Cancer in Patients Hospitalized With Fatty Liver: A Danish Cohort Study, 356
Sotoudehmanesh R. See Merat S
Soykan I
—Reversal of Iron Deficiency Anemia in a Patient With Gastric Antral Vascular Ectasia Treated With Cyproheptadine, 183
Spechler S. See West AB
Spechler SJ
—The Natural History of Dysplasia and Cancer in Esophagitis and Barrett Esophagus, S2
St. Louis TE. See Navarro VJ
Stagg AJ. See Hart AL
Stecevic V
—Successful Treatment of Hepatitis B-Associated Vasculitis With Lamivudine, 451
Stefanadis C
—Chrysohoou C, Paraskevas E, Panagiotakos DB, Xynopoulos D, Dimitroulopoulos D, Petraki K, Papadimitriou C, Karoutsos K, Pitsavos C, Toutouzas PK: Thermal Heterogeneity Constitutes A Marker for the Detection of Malignant Gastric Lesions In Vivo, 215
Takeuchi K
—Tsuzuki Y, Ando T, Sekihara M, Hara T, Kori T, Kuwano H: The Diagnosis and Treatment of Adult Intussusception, 18
—Ohno Y, Tsuzuki Y, Ando T, Sekihara M, Hara T, Kuwano H: *Helicobacter pylori* Infection and Early Gastric Cancer, 321
Tambaro R. See Daniele B
Tamura M. See Yamamoto T
Tarquini M. See Papi C
Tedeschi A
—Chronic Autoreactive Urticaria in a Patient with Ulcerative Colitis, 454
Thulstrup AM. See Sørensen HT
Thuluvath PJ
—Imperio D, Nair S, Cameron JL: Chronic Pancreatitis: Long-Term Pain Relief With or Without Surgery, Cancer Risk, and Mortality, 159
Todaro I. See Bargiggia S
Tomassetti P. See Pezzilli R
Topazian M. See Landi K
Tosetti C
—A Young Girl With Recurrent Severe Abdominal Pain After Appendicectomy, 282
Toutouzas PK. See Stefanadis C
Tözün N. See Özdoğan O
Trabucchi E. See Morandi E
Traube M. See West AB
Tremosa G. See Sese E
Tseng J-H. See Chen Y-C
Tsiakos S. See Anagnostopoulos GK
Tsuzuki Y. See Takeuchi K
Tursi A
—Brandimarte G: The Symptomatic and Histologic Response to a Gluten-Free Diet in Patients With Borderline Enteropathy, 13
—Brandimarte G, Giorgetti GM: Prevalence of Antitissue Transglutaminase Antibodies in Different Degrees of Intestinal Damage in Celiac Disease, 219

Ullman TA
—Dysplasia and Colorectal Cancer in Crohn Disease, S75
Utsumi H. See Matsunaga K
Uygur-Bayramiçli O
—Hyperprolactinemia Caused by Azathioprine, 79
Uzunalimoglu O. See Serinoz E

Vaezi MF
—Gastroesophageal Reflux Disease and the Larynx, 198
Vallone P. See Daniele B
van Rossum LGM. See Laheij RJF
Varadarajulu S
—Patient Compliance for Endoscopic Procedures, 80
Vardas E. See Chatzicostas C
Varli M. See Serinoz E
Vasey FB. See McIlwain L
Venu RP. See Chandrashekar L
Verbeek ALM. See Laheij RJF
Villari D. See Basile G
Vilstrup H. See Sørensen HT

Wald A
—Is Chronic Use of Stimulant Laxatives Harmful to the Colon?, 386
Wallace MB. See Fickling WE
Wang T. See West AB
Wang TC. See Zivny J
Watanabe K. See Gunji T
West AB. See Floch MH
West AB. See Yang G-Y
West AB
—Traube M, Spechler S, Goldblum J, Boyce HW, Robert M: Can Therapy and Surveillance Prevent Cancer of the Esophagus?, S26
—Fisher R, Kapadia C, Genta R, Wang T, Lauwers G: What and Whom to Treat With Metaplasia?, S61
—Proctor D, Itzkowitz S, Loftus E, Nair P: Does Treatment of Inflammatory Bowel Disease Prevent Cancer?, S94
Weston BR
—Helper DJ, Rex DK: Positive Predictive Value of Endoscopic Features Deemed Typical of Gastric Fundic Gland Polyps, 399
Wilcox CM
—Response to Letter by F.A. Granderath et al., 182
Wiley TE. See Cotler SJ
Wong W-M
—Reversal of Protein-Losing Enteropathy by Liver Transplantation, 86
Worman HJ. See Larghi A

Xiol X. See Sese E
Xynopoulos D. See Stefanadis C

Yada K. See Matsumoto T
Yadav D
—Pitchumoni CS: Issues in Hyperlipidemic Pancreatitis, 54
Yamada T
—Miwa H, Fujino T, Hirai S, Yokoyama T, Sato N: Improvement of Gastric Atrophy After *Helicobacter pylori* Eradication Therapy, 405
Yamakawa M. See Kitamoto Y
Yamamoto K. See Matsunaga K
Yamamoto T
—Tamura M, Ishii T, Anjiki H, Hattori K, Saitoh M, Sanaka M, Kuyama Y: Urinary Antibody Titers to *Helicobacter pylori* and an Impact of Clinical Characteristics, 329
Yang CH. See Jang TJ
Yang G-Y
—West AB: What Do Eosinophils Tell Us in Biopsies of Patients With Inflammatory Bowel Disease?, 93
Yang H. See Abreu MT
Yantiss R. See Zivny J
Yao FY
—Dramatic Reduction of the α-Fetoprotein Level After Lamivudine Treatment of Patients with Chronic Hepatitis B Virus Infection and Cirrhosis, 440
Yapar Z. See Gumurdulu Y
Yazgan Y
—Demirtürk L, Özel AM, Yildirim Ş, Ercan M: Impact of Imprint Cytology in Detecting Short Segment Barrett's Esophagus, 126
Yeh C-N. See Chen Y-C
Yen T
—Keeffe EB, Ahmed A: The Epidemiology of Hepatitis C Virus Infection, 47
Yildirim Ş. See Yazgan Y
Yokosuka O. See Chiba T
Yokoyama T. See Yamada T
Younossi ZM
—Mullen KD, Hodnick S, Barnes DS, Carey WD, McCullough AC, Easley K, Gramlich T, Liebermann BY: Triple Combination of Interferon Alpha-2b, Ribavirin, and Amantadine for Treatment of Chronic Hepatitis C, 427
Yousef WI. See Massoud OI
Yurdaydin C. See Serinoz E

Zamir D
—Prediction of Fatty Liver: Comparison of Body Mass Index, Visceral Fat, and Subcutaneous Fat, 281
Zivny J
—Wang TC, Yantiss R, Kim KH, Houghton J: Role of Therapy or Monitoring in Preventing Progression to Gastric Cancer, S50
Zlatanic J
—Korelitz BI, Rajapakse R, Kim PS, Rubin SD, Baiocco PJ, Panagopoulos G: Complications of Pregnancy and Child Development After Cessation of Treatment With 6-Mercaptopurine for Inflammatory Bowel Disease, 303

J Clin Gastroenterol 2003;36(5):462–468.

© 2003 Lippincott Williams & Wilkins, Inc.

SUBJECT INDEX FOR VOLUME 36

Abdominal pain, recurrent, after appendicectomy (letter), 282
Abscess, liver
  after dental treatment (letter), 369
  Klebsiella (letter), 186
Achalasia, intrasphincteric botulinum toxin versus pneumatic balloon dilation for, 209
Acute necrotizing pancreatitis, early peripheral lymphocyte activation and, 360
Acute physiologic and chronic health evaluation (APACHE-II/III)
  in predicting severity in acute pancreatitis (editorial), 195
  scoring systems of, versus Balthazar CT severity index for acute pancreatitis outcome prediction, 253
Adenocarcinoma
  Barrett esophagus and, S19
  complicating Crohn's disease, 332
  in Crohn's disease, S75
  gastric, defining pathologic diagnosis of, S37
  risk of in Barrett esophagus, S2
Adenoma, histologic diagnosis of dysplasia in, S63
Adult annular pancreas, symptomatic, 446
Adult intussusception, diagnosis and treatment of, 18
Albumin gradient ascites, with tuberculous peritonitis (letter), 82
Alcohol
  abstinence of, in survival with alcoholic cirrhosis, 170
  in hepatitis C (editorial), 100
  in hypertriglyceridemia, 54
  interaction with hepatitis C and outcome, 242
Alcoholic cirrhosis
  Escherichia coli myonecrosis in, 443
  hepatitis C virus infection and alcohol abstinence in survival with, 170
Amantadine, for chronic hepatitis C, 427
5-Aminosalicylic acid, protective effect of on *Helicobacter pylori* infection in inflammatory bowel disease, 22
Aminotransferase serum levels, with nonalcoholic steatohepatitis (letter), 371
Amoxicillin, with omeprazole plus azithromycin for eradication of *Helicobacter pylori* infection, 325
Announcements, 91, 191, 286, 376
Annulus, symptomatic, 446
Antibodies, *Helicobacter pylori*
  B_{12} serum levels and, 130
  in medical students and residents in Brazil, 134
Anti-*Saccharomyces cerevisiae* antibody, elevated levels of (editorial), 5
Antitissue transglutaminase antibodies, prevalence of in intestinal damage with celiac disease, 219
Appendicectomy, recurrent severe abdominal pain after (letter), 282
Appendix, synchronous nonfunctioning neuroendocrine carcinoma of (letter), 452
Arteriovenous malformations, with hereditary hemorrhagic telangiectasia, 149
Ascites
  in hepatic hydrothorax, 75
  high albumin gradient, with tuberculous peritonitis (letter), 82
Autoimmune thrombotic thrombocytopenic purpura, in inflammatory bowel disease (letter), 83
Autonomic neuropathy, gastric emptying time and cisapride effect on in cirrhotic patients, 175
Autoreactive urticaria, in ulcerative colitis (letter), 454
Azathioprine
  hepatoxicity of in Crohn's disease treatment, 234
  hyperprolactinemia caused by (letter), 79
  measuring levels of metabolites in inflammatory bowel disease management, 390
  6-mercaptopurine and, optimizing therapeutic potential of in inflammatory bowel disease treatment (editorial), 379
Azithromycin, omeprazole plus, with amoxicillin or tinidazole for eradication of *Helicobacter pylori* infection, 325

B_{12} vitamin, serum levels of and *Helicobacter pylori* infection, 130
Bacterial empyema, spontaneous, with hepatic hydrothorax, 75
Balloon dilation, pneumatic, versus intrasphincteric botulinum toxin for primary achalasia, 209
Balthazar score, versus APACHE II and III scoring systems for acute pancreatitis outcome prediction, 253
Barrett esophagus
  defining dysplasia in, S19
  endoscopic findings and what to biopsy in, S6
  natural history of dysplasia and cancer in, S2
  short segment, imprint cytology in detecting, 126
Bile, cholesterol crystals in with acalculous gallbladder disease, 364
Biliary cirrhosis, increased incidence of fungal infections in (letter), 369
Biliary tract stones, sonographic prevalence of in inflammatory bowel disease, 417
Biopsy
  in Barrett esophagus, S6
  in defining dysplasia in Barrett esophagus, S19
  in inflammatory bowel disease (editorial), 93
Bleeding, after endoscopic treatment of gastroduodenal Dieulafoy's lesion, 310
Blood clot, autologous, in unresectable hepatocellular carcinoma, 347
Blood product transfusion, in hepatitis C virus transmission, 47
Body mass index, in predicting fatty liver (letter), 281
Bond, John H., biography of, 289
Bone marrow transplantation
  causes and risk factors for following, 421
  graft-versus-host disease after, 179
Book/CD ROM/DVD reviews
  Gastrointestinal and liver disease: pathophysiology/diagnosis/management, 7th Edition, Vols. 1 and 2, 189
  Gastrointestinal immunology, 375
  Hepatitis B and C: management and treatment, 89
  Hepatology: a textbook of liver diseases, 4th edition, 375
  Infections of the gastrointestinal tract, 2nd Edition, 189
  Living with hepatitis C: a survivor's guide, 89
  Practical gastroenterology, 89
  Therapeutic gastrointestinal endoscopy, 189
Borderline enteropathy (editorial), 6
  symptomatic and histologic response to gluten-free diet in, 13
Botulinum toxin, intrasphincteric, versus pneumatic balloon dilation for primary achalasia, 209
Branch duct type intraductal papillary mucinous neoplasms, pancreatic, optimal management of, 261
Brazil, seroprevalence of *Helicobacter pylori* antibodies in, 134
Burkitt's lymphoma, complicating Crohn's disease, 332

13C-octanoic acid breath test, half emptying time in (letter), 284
C-reactive protein, in predicting severity in acute pancreatitis (editorial), 195
C_{13}-urea breath test, for *Helicobacter pylori* infection, 22
Cancer
  colorectal
    chemotherapy with fluorouracil and folinic acid for in elderly patients, 228
    chronic stimulant laxative use and, 386
    coprocytobiology for, S84
    in Crohn disease, S75
  enteral nutritional support for, 297
  gastric
    defining pathologic diagnosis of, S37
    family history of, 204
    Helicobacter pylori infection and, 321
    with positive familial history of cancer, clinicopathology and prognosis of, 30
    preventing progression to, S50
    prevention and early detection of, S44
  natural history of in esophagitis and Barrett esophagus, S2
  prevention of in inflammatory bowel disease, S75
  therapy and surveillance in prevention of, S26
  treatment of inflammatory bowel disease in prevention of, S94
Cancer risk
  after liver transplantation, 436
  in Barrett esophagus, S2
  in inflammatory bowel disease, S70
  with long-term pain relief in chronic pancreatitis, 159
  in patients hospitalized with fatty liver, 356
Candesartan cilexetil-induced severe hepatotoxicity, 273
Carcinogenesis
  colon, in inflammatory bowel disease, S70
  gastric, prevention and early detection of, S44
Carcinoid crisis, with external manipulation of liver metastasis (letter), 87
Carcinoma
  dysplasia-associated, histologic diagnosis of, S63
  endoscopic retrograde cholangiopancreatography for in elderly, 72
  gastric, dysplasia and metaplasia in, S29
  hepatocellular, with hepatitis C virus and alcohol, 242
  intramucosal, Barrett esophagus and, S19
  synchronous nonfunctioning neuroendocrine, of pancreas and appendix (letter), 452
CARD15/NOD2 gene mutations, in Crohn's disease (editorial), 3
Cardiac mucosa, with *Helicobacter pylori*-induced gastritis and reflux esophagitis, 26
Carditis, with *Helicobacter pylori*-induced gastritis, 26

Case-control study, of hepatic resection and percutaneous ethanol injection for small hepatocellular carcinoma, 63
Cassava, tropical chronic pancreatitis and, 337
Cathartic colon, with chronic stimulant laxative use, 386
CD69 count, in acute pancreatitis, 360
Celiac disease
antitissue transglutaminase antibodies in intestinal damage with, 219
borderline, symptomatic and histologic response to gluten-free diet in, 13
Giardia duodenalis confounding diagnosis of (letter), 185
pathogenesis of (editorial), 6
presenting during puerperium (letter), 81
with T-cell lymphoma, 144
Cell cycle, hepatitis B core antigen relation to, 269
Chemoembolization, for unresectable hepatocellular carcinoma, 347
Chemoprevention, of gastric cancer, S50
Chemotherapy, with fluorouracil and folinic acid for advanced colorectal cancer, 228
Child development, complications of after cessation of 6-mercaptopurine for inflammatory bowel disease, 303
Cholangiopancreatography, safety and effectiveness of in elderly patients, 72
Cholecystitis, acute acalculous, clinical features of, 166
Choledocholithiasis, endoscopic ultrasound in, 103
Cholestasis, acute, candesartan cilextil-induced, 273
Cholesterol crystals, morphology of in acalculous gallbladder disease, 364
Chromoendoscopy
in Barrett esophagus, S6
for metaplasia and dysplasia in gastric atrophy, S29
Cirrhosis
alcoholic, *Escherichia coli* myonecrosis in, 443
esophageal varices in hepatocellular carcinoma with, 68
gastric emptying time and cisapride effect on autonomic neuropathy with, 175
in hepatic hydrothorax, 75
hepatitis C virus and, 242
alcohol abstinence in survival with, 170
liver
esophageal varices in hepatocellular carcinoma with, 68
in hepatic hydrothorax, 75
hepatitis C virus infection and alcohol abstinence in survival with, 170
primary biliary, increased incidence of fungal infections in (letter), 369
reduced level of α-fetoprotein after lamivudine treatment for, 440
Cisapride, gastric emptying time and in cirrhosis with autonomic neuropathy, 175
Clinical characteristics, urinary antibody titers to *Helicobacter pylori* and impact of, 329
Clinical trials, of probiotics for inflammatory bowel disease, 111
Clinicopathology, of gastric cancer with positive familial history of cancer, 30
Clostridium difficile infection, associated with collagenous colitis (letter), 285
Cobalamin deficiency, in gastric atrophy, S29
Colitis
collagenous, associated with *Clostridium difficile* infection (letter), 285
verocytotoxin-producing *Escherichia coli*, 44
Collagenous colitis, associated with *Clostridium difficile* infection (letter), 285
Collagenous sprue, with extensive T-cell lymphoma, 144
Colon
carcinogenesis of in inflammatory bowel disease, S70
chronic stimulant laxative use and, 386
coprocytobiology for cancer of, S84
diseases of, cellular elements from stool in pathophysiology of, S84
perforations of with verocytotoxin-producing *Escherichia coli* colitis, 44
Colonoscopy, in cancer prevention in inflammatory bowel disease, S79
Colorectal cancer
chemotherapy with fluorouracil and folinic acid for in elderly patients, 228
chronic stimulant laxative use and, 386
coprocytobiology for, S84
in Crohn disease, S75
prevention of in inflammatory bowel disease, S79
sporadic, in inflammatory bowel disease, S70
Combination therapy, for chronic hepatitis C, 427
Complement, low levels of in hepatic hydrothorax, 75
Complementary medicine, in gastroenterology (letter), 453
Compliance, for endoscopic procedures (letter), 80
Complications
after cessation of 6-mercaptopurine for inflammatory bowel disease during pregnancy, 303
of Crohn's disease, 332
of tropical chronic pancreatitis, 337
Computed tomography
for adult intussusception, 18
Balthazar severity index of versus APACHE II and III scoring systems for acute pancreatitis outcome prediction, 253
Constipation, chronic stimulant laxative use for, 386
Coprocytobiology, in pathophysiology of colonic disease, S84
Crohn's disease
clinical and demographic characterization of in Israel, 8
defining subtypes of (editorial), 3
dysplasia and colorectal cancer in, S75
eosinophils in biopsies for (editorial), 93
hepatotoxicity of 6-thioguanine for, 234
hypersensitivity and leukocytoclastic vasculitis secondary to infliximab for, 411
immunohistochemical study of intestinal eosinophils in, 120
primary intestinal lymphoma complicating, 332
probiotics for, 111
severe recurrent, infliximab for, 238
Crystallization, in acalculous gallbladder disease, 364
Cyclosporin A, with interferon alfacon-1, for hepatitis C in nonresponders, 352
Cyclosporin hepatotoxicity, causes and risk factors for following bone marrow transplantation, 421
Cyproheptadine, reversal of iron deficiency anemia with (letter), 183
Cytology
in Barrett esophagus, S6
in defining dysplasia in Barrett esophagus, S19

Demographics
of hepatitis C virus infection transmission, 47
of Jewish Crohn's disease in Israel, 8
Dental treatment, multiple liver abscesses after (letter), 369
Diabetes
fibrocalculous pancreatic, 337
in hypertriglyceridemia, 54
Diagnosis
of adult intussusception, 18
of celiac disease with *Giardia* duodenalis (letter), 185
of dysplasia, dysplasia-associated lesion or mass, and adenoma, S63
of gastroesophageal reflux disease, 198
of metaplasia, atrophy, dysplasia, and gastric adenocarcinoma, S37
Diarrhea
antibiotic-associated, *Saccharomyces boulardii* for, 41
Saccharomyces cerevisiae-associated, in immunocompetent ulcerative colitis patients, 39
Dieulafoy's lesion
management of in endoscopic era (editorial), 294
outcome of endoscopic treatment of with rubber band ligation and thermal/injection therapy, 310
Doppler studies, in Dieulafoy's lesion (editorial), 294
Drug-induced hepatotoxicity, 273
Ductopenia, candesartan cilextil-induced hepatotoxicity and, 273
Duodenal ulcer, *Helicobacter pylori*-positive obese people (letter), 184
Dyspepsia, nonulcer
eradication of *Helicobacter pylori* in (editorial), 291
Helicobacter pylori infection treatment of, 315
number of responses on review of systems questionnaire predicting diagnosis of, 222
Dysplasia
in Crohn's disease, S75
defining in Barrett esophagus, S19
defining pathologic diagnosis of, S37
gastric atrophy and, S29
histologic diagnosis of, S63
histologic diagnosis of lesions associated with, S63
natural history of in esophagitis and Barrett esophagus, S2
pathologic and clinical significance of in gastrointestinal tract (editorial), S1
polypoid, in inflammatory bowel disease, S70

Editorials
Borderline enteropathies, 6
Defining subtypes of Crohn's disease patients, 3
Defining the pathologic and clinical significance of dysplasia and metaplasia in the gastrointestinal tract, S1
Eradication of *Helicobacter pylori* in nonulcer dyspepsia, 291
Hepatitis C and alcohol, 100
Improvement of gastric atrophy after cure of *Helicobacter pylori*, 382
Management of Dieulafoy's lesion in the endoscopic era, 294
Management of pain in chronic pancreatitis, 98
Optimal management of nonalcoholic fatty liver/steatohepatitis, 193
Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease, 379
Predicting severity in acute pancreatitis, 195
Saccharomyces: Is it a probiotic or a pathogen and what is the significance of an elevated anti-*S. cerevisiae* antibody?, 5
Use of lactoferrin for *Helicobacter pylori* eradication, 384
What do eosinophils tell us in biopsies of patients with inflammatory bowel disease?, 93

Elderly patients
chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in, 228
endoscopic retrograde cholangiopancreatography in, 72
Elta, Grace Helen, biography of, 1
Embolization
hereditary hemorrhagic telangiectasia and, 149
for unresectable hepatocellular carcinoma, 347
Empyema, spontaneous bacterial, with hepatic hydrothorax, 75
Endoscopic band ligation, in Dieulafoy's lesion (editorial), 294
Endoscopic gastrostomy, stent retrieval rat tooth forceps in placement of (letter), 80
Endoscopic injection sclerotherapy, for esophageal varices in cirrhotic patients with hepatocellular carcinoma, 68
Endoscopic retrograde cholangiopancreatography, safety and effectiveness of in elderly patients, 72
Endoscopic ultrasonography
for metaplasia and dysplasia in gastric atrophy, S29
in upper gastrointestinal disorders, 103
Endoscopy
in Barrett esophagus, S6
compliance for (letter), 80
in detecting malignant gastric lesions in vivo, 215
for gastroduodenal Dieulafoy's lesion with rubber band ligation and thermal/injection therapy, 310
in management of Dieulafoy's lesion (editorial), 294
positive predictive value of in fundic gland polyps, 399
Endosonography, in upper gastrointestinal disorders, 103
Enteral nutritional support, in cancer patients, 297
Enteropathy
antitissue transglutaminase antibodies prevalence and, 219
borderline (editorial), 6
symptomatic and histologic response to gluten-free diet in, 13
Environmental factors, in gastric cancer, 204
Eosinophils
immunohistochemical study of in inflammatory bowel disease, 120
in inflammatory bowel disease (editorial), 93
Epidemiology
of cancer risk in patients hospitalized with fatty liver, 356
of *Helicobacter pylori* antibodies seroprevalence in medical students in Brazil, 134
of hepatitis C virus infection, 47
Epinephrine injection, outcome of for gastroduodenal Dieulafoy's lesion, 310
Epithelial tumors, prevention and early detection of, S44
Erythematous maculopapular eruption, ribavirin-associated in chronic hepatitis C virus (letter), 283
Escherichia coli EH 0157:H7 colitis, verocytotoxin-producing, 44
Escherichia coli myonecrosis, in alcoholic cirrhosis, 443
Esophagitis
healed with pantoprazole (letter), 78
natural history of dysplasia and cancer in, S2
Esophagus
anatomy of, S6
cancer of
enteral nutritional support for, 297
therapy and surveillance in prevention of, S26
mucosa-associated lymphoid tissue lymphoma of, 414
varices of in cirrhotic patients with hepatocellular carcinoma, 68
Estrogens, in hypertriglyceridemia, 54
Ethanol injection, percutaneous, for small hepatocellular carcinoma, 63

Familial adenomatous polyposis syndrome, in gastric carcinoma, S29
Family history, in gastric cancer, 30, 204
Fatty liver
cancer risk in patients with, 356
nonalcoholic
optimal management of (editorial), 193
probucol for, 266
predictors of (letter), 281
α-Fetoprotein, reduced level of after lamivudine for chronic hepatitis B virus and cirrhosis, 440
Fibrocalculous pancreatic diabetes, with tropical chronic pancreatitis, 337
Fine-needle aspiration, in upper gastrointestinal disorders, 103
Fish oil supplements, for recurrent pancreatitis, 54
Fluorouracil, for colorectal cancer in elderly patients, 228
Folinic acid, for colorectal cancer in elderly patients, 228
Follow-up, of gluten-free diet in borderline celiac disease, 13
Functional gastrointestinal disorders, number of responses on review of systems questionnaire predicting diagnosis of, 222
Fundic gland polyps, positive predictive value of endoscopic features of, 399
Fungal infections
in advanced primary biliary cirrhosis (letter), 369
causes and risk factors for following bone marrow transplantation, 421
Fungemia, *Saccharomyces cerevisiae*, after *Saccharomyces boulardii* treatment in immunocompromised patients, 41

Gallbladder disease, acalculous, cholesterol crystal morphology in, 364
Gallstones
endoscopic retrograde cholangiopancreatography for in elderly, 72
sonographic prevalence of in inflammatory bowel disease, 417
Gangrene, in acute acalculous cholecystitis, 166
Gas gangrene, in alcoholic cirrhosis, 443
Gastrectomy, partial, gastric carcinoma and, S44
Gastric acid secretion, in gastric cancer, S50
Gastric adenocarcinoma, defining pathologic diagnosis of, S37
Gastric antral vascular ectasia, reversal of iron deficiency anemia with cyproheptadine in (letter), 183
Gastric atrophy
after cure of *Helicobacter pylori* (editorial), 382
clinical perspective on, S29
defining pathologic diagnosis of, S37
in gastric cancer, 204
in gastric carcinoma, S50
improvement of after *Helicobacter pylori* eradication, 405
Gastric cancer
defining pathologic diagnosis of, S37
diffuse-type with *Helicobacter pylori* infection, 321
early, *Helicobacter pylori* infection and, 321
family history of, 204
intestinal-type with *Helicobacter pylori* infection, 321
with positive familial history of cancer, clinicopathology and prognosis of, 30
preventing progression to, S50
Gastric carcinoma, dysplasia and metaplasia in, S29
Gastric emptying time, cisapride and in cirrhosis with autonomic neuropathy, 175
Gastric epithelial dysplasia, gastric carcinoma and, S50
Gastric lavage, in Dieulafoy's lesion (editorial), 294
Gastric malignancy, thermal heterogeneity in detecting, 215
Gastric neoplasms, prevention and early detection of, S44
Gastric polyps, fundic gland, positive predictive value of endoscopic features of, 399
Gastric varices, improving clinical course of (letter), 372
Gastritis
defining pathologic diagnosis of, S37
Helicobacter pylori-induced, carditis associated with, 26
prevention and early detection of carcinogenesis in, S44
Gastroduodenal Dieulafoy's lesion, outcome of endoscopic treatment of with rubber band ligation and thermal/injection therapy, 310
Gastroenterology consultations, temporal trends in, 34
Gastroesophageal reflux disease (GERD)
carditis and, 26
larynx and, 198
worsening of symptoms in singers during performances, 403
Gastrointestinal hemorrhage
in Dieulafoy's lesion (editorial), 294
massive, infliximab for severe recurrent Crohn's disease presenting with, 238
Genetic mutations, in Crohn's disease (editorial), 3
Genetic predisposition, of Crohn's disease in Jewish population, 8
Genetics, in gastric cancer, 204, S50
Giardia duodenalis, in diagnosis of celiac disease (letter), 185
Gluten diseases, classification of (editorial), 6
Gluten enteropathy, abnormalities of (editorial), 6
Gluten-free diet, symptomatic and histologic response to in borderline enteropathy, 13
Graft-versus-host disease
causes and risk factors for following bone marrow transplantation, 421
chronic, complicated by acute hepatitis B, 179

Half emptying time, in 13C-octanoic acid breath test (letter), 284
HBcAg, nuclear localization of, 269
Head and neck cancer, enteral nutritional support for, 297
Helicobacter pylori antibodies, seroprevalence of in medical students and residents in Brazil, 134
Helicobacter pylori-induced gastritis, carditis associated with, 26
Helicobacter pylori infection
amoxicillin or tinidazole with omeprazole plus azithromycin for eradication of, 325
early gastric cancer and, 321
eradication of in nonulcer dyspepsia (editorial), 291
in family history of gastric cancer, 204
in gastric atrophy, S29
adenocarcinoma and, S37
in gastric neoplasms, S44
improvement of gastric atrophy after eradication of, 405
improvement of gastric atrophy after eradication of (editorial), 382

lactoferrin for eradication of, 396
lactoferrin for eradication of (editorial), 384
monitoring of in preventing gastric cancer, S50
obesity and incidence of (letter), 184
protective effect of 5-aminosalicylic acid on, 22
serum vitamin B_{12} levels and, 130
treatment of
in metaplasia, S61
in nonulcer dyspepsia, 315
urinary antibody titers to and clinical characteristics of, 329
Helicobacter pylori test-and-treat policy, knowledge of in surgeons and internists, 139
Hemodialysis, in hepatitis C virus transmission, 47
Hemoglobinuria, with ribavirin treatment, 367
Hemorrhagic colitis, verocytotoxin-producing *Escherichia coli*, 44
Hepatic hydrothorax, low complement levels and opsonic activity in, 75
Hepatic inflammation, alcoholism in (editorial), 100
Hepatic injury, by paracetamol intoxication, successful treatment of (letter), 372
Hepatic resection, for small hepatocellular carcinoma, 63
Hepatitis B core antigen, nuclear localization of in relation to liver injury, hepatocyte proliferation, and viral load, 269
Hepatitis B virus
causes and risk factors for following bone marrow transplantation, 421
chronic, reduced level of α-fetoprotein after lamivudine treatment for, 440
in chronic graft-versus-host disease, 179
reactivation of after kidney transplantation, 276
remission of with lamivudine in renal allograft recipient (letter), 187
Hepatitis B virus-associated vasculitis, successful treatment of with lamivudine (letter), 451
Hepatitis C virus
alcohol abstinence and in cirrhosis, 170
alcohol and (editorial), 100
alcohol and outcome of, 242
causes and risk factors for following bone marrow transplantation, 421
chronic, combination interferon alpha-2b, ribavirin and amantadine for, 427
combination cyclosporin A and interferon alfacon-1 for, 352
epidemiology of, 47
erythematous maculopapular eruption due to ribavirin in (letter), 283
hemoglobinuria with ribavirin treatment for, 367
identification of patients with in New Haven County primary care practices, 431
Hepatobiliary lesions, sonographic prevalence of in inflammatory bowel disease, 417
Hepatocellular carcinoma
esophageal varices in cirrhotic patients with, 68
hepatic resection and percutaneous ethanol injection for, 63
with hepatitis C virus and alcohol, 242
treatment of unresectable, 347
Hepatocyte proliferation, hepatitis B core antigen relation to, 269
Hepatotoxicity
with 6-thioguanine therapy for Crohn's disease, 234
candesartan cilextil-induced severe, 273
causes and risk factors for following bone marrow transplantation, 421
Hereditary hemorrhagic telangiectasia, liver disease in, 149
Hiatus hernia, with gastroesophageal reflux disease, worsening symptoms of in singers during performances, 403
Histologic grading, of dysplasia in Barrett esophagus, S19
Histology
after *Helicobacter pylori* eradication, 405
of borderline enteropathy, 13
of dysplasia, dysplasia-associated lesion or mass, and adenoma, S63
HIV-positive patients, *Escherichia coli* colitis in, 44
Hydrothorax, low complement levels and opsonic activity in, 75
Hyperlipidemia, in pancreatitis, 54
Hyperlipidemic pancreatitis, issues in, 54
Hyperlipoproteinemias, familial, 54
Hyperprolactinemia, azathiprine-induced (letter), 79
Hypersensitivity vasculitis, with leukocytoclastic vasculitis secondary to infliximab, 411
Hypertriglyceridemia, in hyperlipidemic pancreatitis, 54

IgA antiendomysium antibodies, in detecting intestinal damage in celiac disease, 219
IgA anti-gliadin antibodies, in detecting intestinal damage in celiac disease, 219
Immunocompromised patients, *Saccharomyces cerevisiae* fungemia after *Saccharomyces boulardii* treatment in, 41
Immunohistochemistry
of intestinal eosinophils in inflammatory bowel disease, 120
of tropical chronic pancreatitis, 337
Immunologic disorders, in acute pancreatitis, 360
Immunomodulators, measuring levels of in inflammatory bowel disease management, 390
Immunosuppression
in cancer risk after liver transplantation, 436
in hepatitis B virus reactivation after kidney transplantation, 276
in Jewish Crohn's disease in Israel, 8
Imprint cytology, in detecting short segment Barrett's esophagus, 126
Inflammatory bowel disease
autoimmune thrombotic thrombocytopenic purpura with (letter), 83
colon carcinogenesis in, S70
complications of pregnancy and child development after cessation of 6-mercaptopurine for, 303
coprocytobiology for, S84
eosinophils in biopsies for (editorial), 93
hepatotoxicity of 6-thioguanine for, 234
histologic diagnosis of, S63
immunohistochemical study of intestinal eosinophils in, 120
measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in management of, 390
monitoring to prevent cancer in, S79
optimizing therapeutic potential of azathioprine/6-mercaptopurine for (editorial), 379
probiotics for, 111
protective effect of 5-aminosalicylic acid on *Helicobacter pylori* infection in, 22
sonographic prevalence of liver steatosis and biliary tract stones in, 417
treatment of in cancer prevention, S94
Infliximab
hypersensitivity and leukocytoclastic vasculitis secondary to, 411
red man syndrome and (letter), 186
for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhage, 238
Injection drug use, in hepatitis C virus transmission, 47
Inner city hospital, temporal trends in inpatient gastroenterology consultations in, 34
Inpatient gastroenterology consultations, temporal trends in, 34
Interferon, with cyclosporin A for hepatitis C in nonresponders, 352
Interferon alpha-2b, for chronic hepatitis C, 427
Internal medicine, knowledge regarding *Helicobacter pylori* test-and-treat policy in, 139
Intestinal metaplasia
in gastric cancer, 204
with *Helicobacter pylori* infection, 321
Intestinal mucosa, immunohistochemical study of eosinophils in, 120
Intramucosal carcinoma
Barrett esophagus and, S19
defining pathologic diagnosis of, S37
Intussusception, diagnosis and treatment of in adults, 18
Iron deficiency anemia, reversal of with cyproheptadine in gastric antral vascular ectasia (letter), 183
Irritable bowel syndrome, number of responses on review of systems questionnaire predicting diagnosis of, 222
Israel, clinical and demographic characterization of Jewish Crohn's disease in, 8

Jaundice, endoscopic retrograde cholangiopancreatography for in elderly, 72
Jejunostomy tube, stent retrieval rat tooth forceps in placement of (letter), 80

Kidney transplantation, hepatitis B virus reactivation after, 276
Klebsiella liver abscess (letter), 186
Knowledge, of *Helicobacter pylori* test-and-treat policy in surgeons and internists, 139

Lactobacillus, in inflammatory bowel disease treatment, 111
Lactoferrin
for *Helicobacter pylori* eradication, 396
for *Helicobacter pylori* eradication (editorial), 384
Lamivudine
for hepatitis B-associated vasculitis (letter), 451
in hepatitis B virus remission with in renal allograft recipient (letter), 187
reduced level of α-fetoprotein after treatment with in chronic hepatitis B virus and cirrhosis, 440
Laryngoscopy, for gastroesophageal reflux disease diagnosis, 198
Larynx, gastroesophageal reflux disease and, 198
Laxatives, effects of chronic use of, 386
Letters to editor
Association of *Clostridium difficile* infection with collagenous colitis, 285
Autoimmune thrombotic thrombocytopenic purpura: a severe complication of inflammatory bowel disease, 83
Carcinoid crisis induced by external manipulation of liver metastasis, 87
Celiac disease presenting during puerperium, 81
Characterization of long-term outcomes after toupet fundoplication, 182
Characterization of long-term outcomes after toupet fundoplication: authors' response, 182
Chronic autoreactive urticaria in a patient with ulcerative colitis, 454
Complementary medicine in gastroenterology: more than a fad?, 453
The "corrected" half emptying time is a valueless parameter in the 13C-octanoic acid breath test: misuse of the regression analysis, 284

Does high albumin gradient ascites accompany tuberculous peritonitis?, 82
Erythematous maculopapular eruption due to ribavirin administration in a patient with chronic hepatitis C, 283
The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis, 371
Giardia duodenalis: a confounding factor for the diagnosis of celiac disease, 185
How should we improve the clinical course of patients with gastric varices?, 372
Hyperprolactinemia caused by azathiprine, 79
The incidence of *Helicobacter pylori* is not increased in obese people, but the risk of duodenal ulcer is higher in *H. pylori*-positive people of high obesity, 184
Increased incidence of fungal infections in advanced primary biliary cirrhosis, 369
Klebsiella liver abscess, 186
Metronidazole and mental confusion, 373
Multiple liver abscesses after dental treatment, 369
Patient compliance for endoscopic procedures, 80
Prediction of fatty liver: comparison of body mass index, visceral fat, and subcutaneous fat, 281
Red man syndrome and infliximab, 186
A renal allograft recipient with viral-burden, steatoviral, and fibroviral hepatitis B who achieved remission with lamivudine, 187
Reversal of iron deficiency anemia in a patient with gastric antral vascular ectasia treated with cyproheptadine, 183
Reversal of protein-losing enteropathy by liver transplantation, 86
Sclerosing cholangitis associated with systemic sarcoidosis, 84
Severe esophagitis healed in less than a week with intravenous pantoprazole, 78
Successful treatment of acute hepatic injury caused by paracetamol intoxication in a late-referral patient by *N*-acetylcysteine, 372
Successful treatment of hepatitis B-associated vasculitis with lamivudine, 451
Synchronous nonfunctioning neuroendocrine carcinoma of the pancreas and appendix, 452
Use of mycophenolate mofetil in the treatment of primary sclerosing cholangitis, 86
Use of stent retrieval rat tooth forceps for percutaneous endoscopic gastrostomy/jejunostomy tube placement, 80
A young girl with recurrent severe abdominal pain after appendicectomy, 282
Leukocytoclastic vasculitis, with hypersensitivity vasculitis secondary to infliximab, 411
Lipids, in hyperlipidemic pancreatitis, 54
Liver abscess
Klebsiella (letter), 186
multiple, after dental treatment (letter), 369
Liver disease
chronic, hemoglobinuria with ribavirin treatment for, 367
in hereditary hemorrhagic telangiectasia, 149
identification of patients with in primary care practices, 431
Liver fibrosis, alcoholism in (editorial), 100
Liver injury
causes and risk factors for following bone marrow transplantation, 421
hepatitis B core antigen relation to, 269
mechanisms of with alcohol, 242
by paracetamol intoxication, successful treatment of (letter), 372
Liver metastasis, carcinoid crisis induced by external manipulation of (letter), 87
Liver steatosis, sonographic prevalence of in inflammatory bowel disease, 417
Liver transplantation
hereditary hemorrhagic telangiectasia and, 149
malignancy after with premalignant conditions, 436
reversal of protein-losing enteropathy by (letter), 86
Locoregional treatment, for small hepatocellular carcinoma, 63
Lymphocytes, early activation of in human acute pancreatitis, 360
Lymphoma
mucosa-associated lymphoid tissue of esophagus, 414
new onset after kidney transplantation, 276
non-Hodgkin, premalignant conditions and risk of, 436
primary gastric MALT, prevention and early detection of, S44
primary intestinal, complicating Crohn's disease, 332
primary malignant esophageal, 414
T-cell, collagenous sprue associated with, 144
Lymphoproliferative disease, posttransplantation, premalignant conditions and risk of, 436

Malabsorption, with T-cell lymphoma, 144
Malignancy
after liver transplantation with premalignant conditions, 436
in Crohn disease, S75
gastric, thermal heterogeneity in detecting, 215
Malnutrition, in cancer patients, 297
MALT lymphoma, of esophagus, 414
Markers
for acute pancreatitis (editorial), 195
in detecting malignant gastric lesions in vivo, 215
for intestinal damage in celiac disease, 219
Mass, dysplasia-associated, histologic diagnosis of, S63
Medical students, *Helicobacter pylori* antibodies seroprevalence among in Brazil, 134
Meetings
international, 92, 192, 287, 377
in United States, 91, 191, 286, 376
Mental confusion, metronidazole and (letter), 373
6-Mercaptopurine
complications of pregnancy and child development after cessation of, 303
hepatoxicity of in Crohn's disease treatment, 234
measuring metabolite levels of in inflammatory bowel disease management, 390
6-Mercaptopurine/azathioprine, optimizing therapeutic potential of in inflammatory bowel disease treatment (editorial), 379
Meta-analysis
of eradication of *Helicobacter pylori* in nonulcer dyspepsia (editorial), 291
of *Helicobacter pylori* infection treatment of nonulcer dyspepsia, 315
Metaplasia
defining pathologic diagnosis of, S37
gastric atrophy and, S29
intestinal
in gastric cancer, 204
in gastric carcinoma, S50
with *Helicobacter pylori* infection, 321
pathologic and clinical significance of in gastrointestinal tract (editorial), S1
what and whom to treat with, S61
Metastasis
liver, carcinoid crisis induced by external manipulation of (letter), 87
6-Methylmercaptopurine, measuring levels of in inflammatory bowel disease management, 390
Metronidazole, mental confusion and (letter), 373
Molecular genetics, of colon carcinogenesis in inflammatory bowel disease, S70
Monitoring, to prevent cancer in inflammatory bowel disease, S79
Morphology, of branch duct type intraductal papillary mucinous neoplasms of pancreas, 261
Mortality rate, with long-term pain relief in chronic pancreatitis, 159
Multivariate analysis, of survival with hepatitis C virus and alcohol abstinence in alcoholic cirrhosis, 170
Mycobacterium fortuitum, perianal fistulae caused by, 147
Mycophenolate mofetile, for primary sclerosing cholangitis (letter), 86
Myonecrosis, *Escherichia coli*, in alcoholic cirrhosis, 443

N-acetylcysteine, in successful treatment of acute hepatic injury by paracetamol intoxication (letter), 372
Natural history, of dysplasia and cancer in esophagitis and Barrett esophagus, S2
Necrotizing fasciitis, in alcoholic cirrhosis, 443
Neoplasms
branch duct type intraductal papillary mucinous, optimal management of, 261
colonic, pathophysiology of, S84
gastric, prevention and early detection of, S44
upper gastrointestinal, endoscopic ultrasound in, 103
Neuroendocrine carcinoma, synchronous nonfunctioning, of pancreas and appendix (letter), 452
NOD2 gene mutation, in Crohn's disease (editorial), 3
Nonresponders
combination cyclosporin A and interferon alfacon-1 for hepatitis C virus in, 352
combination interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C in, 427
Nonsteroidal anti-inflammatory drugs, in Dieulafoy's lesion (editorial), 294
Nuclear localization, of hepatitis B core antigen, 269
Nutritional support, in cancer patients, 297

Obesity, *Helicobacter pylori* infection incidence and (letter), 184
Omeprazole plus azithromycin, with amoxicillin or tinidazole for eradication of *Helicobacter pylori* infection, 325
Oncology, in family history of gastric cancer, 204
Open-labeled study, of probucol for nonalcoholic steatohepatitis, 266
Opsonic activity, in hepatic hydrothorax, 75
Organ transplantation, in hepatitis C virus transmission, 47
Osler-Weber-Rendu disease. *See* Telangiectasia, hereditary hemorrhagic
Outcomes
after toupet fundoplication (letter), 182
Balthazar score versus APACHE II and III scoring systems in predicting for acute pancreatitis, 253
of endoscopic treatment of gastroduodenal Dieulafoy's lesion with rubber band ligation and thermal/injection therapy, 310
of hepatitis C virus and alcohol, 242

Pain management
in chronic pancreatitis (editorial), 98
long-term, with chronic pancreatitis, 159

Pancreas
branch duct type intraductal papillary mucinous neoplasms of, optimal management of, 261
symptomatic adult annular, 446
synchronous nonfunctioning neuroendocrine carcinoma of (letter), 452
Pancreatitis
acute
early peripheral lymphocyte activation in, 360
predicting severity in (editorial), 195
Balthazar score versus APACHE II and III scoring systems in predicting outcome of, 253
chronic
endoscopic ultrasound in, 103
long-term pain relief in, 159
hyperlipidemic, 54
pain management in (editorial), 98
prevention of, 54
tropical chronic, 337
Pantoprazole, in severe esophagitis healing (letter), 78
Paracetamol intoxication, successful treatment of acute hepatic injury by (letter), 372
Pathology
in diagnosis of metaplasia, atrophy, dysplasia, and gastric adenocarcinoma, S37
of dysplasia and metaplasia in gastrointestinal tract (editorial), S1
of dysplasia in Barrett esophagus, S19
Pathophysiology
of colonic disease, S84
of gastroesophageal reflux disease and larynx, 198
Percutaneous ethanol injection therapy, for unresectable hepatocellular carcinoma, 347
Percutaneous microwave coagulation therapy, for unresectable hepatocellular carcinoma, 347
Perianal fistulae
in Crohn disease, S75
Mycobacterium fortuitum with, 147
Peripheral lymphocytes, early activation of in human acute pancreatitis, 360
Peritonitis, tuberculous, high albumin gradient ascites accompanying (letter), 82
Peutz-Jeghers syndrome, in gastric carcinoma, S29
pH monitoring, for gastroesophageal reflux disease diagnosis, 198
Pharmacogenetics, of 6-methylmercaptopurine and 6-thioguanine nucleotides in inflammatory bowel disease management, 390
Phase II study, of fluorouracil and folinic acid for colorectal cancer in elderly patients, 228
Pneumatic balloon dilation, versus intrasphincteric botuminum toxin for primary achalasia, 209
Polypoid dysplasia, histologic diagnosis of, S63
Polyps, fundic gland, positive predictive value of endoscopic features of, 399
Pregnancy
complications of after cessation of 6-mercaptopurine for inflammatory bowel disease, 303
in hypertriglyceridemia, 54
Premalignant conditions
in family history of gastric cancer, 204
gastric, S29
malignant after liver transplantation and, 436
Primary care, identification of hepatitis C virus patients in, 431
Probiotics
for inflammatory bowel disease, 111
Saccharomyces cerevisiae fungemia after, 41
Probucol, for nonalcoholic steatohepatitis, 266
Prognosis
for acute acalculous cholecystitis, 166
of gastric cancer with positive familial history of cancer, 30
for hospitalized patients with fatty liver, 356
Protein-losing enteropathy, reversal of by liver transplantation (letter), 86
Puerperium, celiac disease presenting during (letter), 81

Radiotherapy, for mucosa-associated lymphoid tissue lymphoma of esophagus, 414
Ranson score, in predicting acute pancreatitis outcome, 253
Red man syndrome, infliximab and (letter), 186
Reflux esophagitis, carditis and, 26
Regression analysis, of half emptying time in 13C-octanoic acid breath test (letter), 284
Renal allograft, remission of hepatitis B virus with lamivudine after (letter), 187
Resection, for adult intussusception, 18
Review of systems questionnaire, predicting diagnosis of functional gastrointestinal disorders, 222
Rheumatoid arthritis, hypersensitivity and leukocytoclastic vasculitis secondary to infliximab for, 411
Ribavirin
for chronic hepatitis C, 427
erythematous maculopapular eruption due to in hepatitis C (letter), 283
hemoglobinuria with, 367
Risk assessment, for survival with hepatitis C virus and alcoholic cirrhosis, 170
Risk factors
in gastric cancer, 204
for liver injury following bone marrow transplantation, 421
for malignancy after liver transplantation, 436
Rubber band ligation, outcome of endoscopic treatment of with, 310

Saccharomyces
boulardii, Saccharomyces cerevisiae fungemia after treatment with in immunocompromised patients, 41
cerevisiae-associated diarrhea, in immunocompetent ulcerative colitis patients, 39
cerevisiae fungemia, after *Saccharomyces boulardii* treatment in immunocompromised patients, 41
as probiotic or pathogen (editorial), 5
Sarcoidosis, systemic, sclerosing cholangitis with (letter), 84
Sclerosing cholangitis
mycophenolate mofetile for (letter), 86
with systemic sarcoidosis (letter), 84
Sclerotherapy, for esophageal varices in cirrhotic patients with hepatocellular carcinoma, 68
Screening, for intestinal damage in celiac disease, 219
Sepsis, causes and risk factors for following bone marrow transplantation, 421
Sexual transmission, of hepatitis C virus, 47
Short gut syndrome, with treatment of adult intussusception, 18
Singer, worsening gastroesophageal reflux symptoms in during performances, 403
Smoking, in Jewish Crohn's disease in Israel, 8
Sphincteroplasty, for long-term pain relief in chronic pancreatitis, 159
Sphincterotomy, for long-term pain relief in chronic pancreatitis, 159
Sprue, collagenous, with extensive T-cell lymphoma, 144
Squamocolumnar mucosal junction, endoscopic findings and biopsy of in Barrett esophagus, S6
Steatohepatitis
fluctuating aminotransferase serum levels with (letter), 371
nonalcoholic
optimal management of (editorial), 193
probucol for, 266
Steatosis
cancer risk with, 356
liver, sonographic prevalence of in inflammatory bowel disease, 417
Stent retrieval rat tooth forceps, for percutaneous endoscopic gastrostomy/jejunostomy tube placement (letter), 80
Stimulant laxatives
effects of chronic use of, 386
mechanisms of action of, 386
Stomach
cancer of
enteral nutritional support for, 297
with positive familial history of cancer, clinicopathology and prognosis of, 30
defining pathologic diagnosis of adenocarcinoma of, S37
Stool, cellular elements from in pathophysiology of colonic disease, S84
Stromal tumors, gastric, prevention and early detection of, S44
Subcutaneous fat, in predicting fatty liver (letter), 281
Subspecialty referrals, for hepatitis C virus identified in primary care, 431
Sulfasalazine, for *Helicobacter pylori* infection in inflammatory bowel disease, 22
Surgeons, knowledge regarding *Helicobacter pylori* test-and-treat policy in, 139
Surgery
for adult intussusception, 18
for long-term pain relief in chronic pancreatitis, 159
Surveillance
in preventing esophageal cancer, S26
in preventing gastric cancer, S50
Surveillance colonoscopy
in cancer prevention in inflammatory bowel disease, S79
of dysplasia and colorectal cancer, S75
Survival rate, with hepatitis C virus and alcohol abstinence in alcoholic cirrhosis, 170
Symptoms, with gluten-free diet in borderline celiac disease, 13

T-cell lymphoma, collagenous sprue associated with, 144
Tc-99m-sulfur colloid scintigraphy, for gastric emptying time in autonomic neuropathy with cirrhosis, 175
Telangiectasia, hereditary hemorrhagic, liver disease in, 149
Temporal trends, in formal inpatient gastroenterology consultations, 34
Therapy, in preventing cancer of esophagus, S26
Thermal/injection therapy, outcome of endoscopic treatment of with, 310
Thermography, in detecting malignant gastric lesions in vivo, 215
6-Thioguanine, hepatotoxicity of in Crohn's disease treatment, 234
6-Thioguanine nucleotide, measuring levels of in inflammatory bowel disease management, 390

Thrombotic thrombocytopenic purpura, autoimmune, in inflammatory bowel disease (letter), 83
Tinidazole, with omeprazole plus azithromycin for eradication of *Helicobacter pylori* infection, 325
Toupet fundoplication, long-term outcomes after (letter), 182
Transcatheter arterial chemoembolization, for unresectable hepatocellular carcinoma, 347
Transmission, of hepatitis C virus infection, 47
Transplantation, hepatitis B virus reactivation after, 276
Triple combination treatment, for chronic hepatitis C virus, 427
Tropical chronic pancreatitis, update on, 337
Trypsinogen activation peptide, in predicting severity in acute pancreatitis (editorial), 195
Tuberculous peritonitis, high albumin gradient ascites accompanying (letter), 82
Tumor necrosis factor inhibitors, hypersensitivity and leukocytoclastic vasculitis secondary to, 411

Ulcerative colitis
  chronic autoreactive urticaria in (letter), 454
  colorectal cancer and, S75
  histologic diagnosis of, S63
  probiotics for, 111
  Saccharomyces cerevisiae-associated diarrhea in, 39
Ultrasonography
  endoscopic
    in Dieulafoy's lesion (editorial), 294
    in upper gastrointestinal disorders, 103
  for liver steatosis and biliary tract stones in inflammatory bowel disease, 417
  for metaplasia and dysplasia in gastric atrophy, S29
Upper gastrointestinal disorders, endoscopic ultrasound in, 103
Urinary antibody titers, to *Helicobacter pylori*, 329
Urticaria, chronic autoreactive, in ulcerative colitis (letter), 454

Vasculitis
  hepatitis B-associated, successful treatment of with lamivudine (letter), 451
  hypersensitivity, with leukocytoclastic vasculitis secondary to infliximab, 411
  leukocytoclastic, with hypersensitivity vasculitis secondary to infliximab, 411
Verocytotoxin-producing *Escherichia coli* EH 0157:H7 colitis, 44
Vertical transmission, of hepatitis C virus, 47
Viral load, hepatitis B core antigen relation to, 269
Viral reactivation, after kidney transplantation, 276
Viral replication, of hepatitis B core antigen in relation to liver injury, hepatocyte proliferation, and viral load, 269
Visceral fat, in predicting fatty liver (letter), 281
Vocal performance, worsening gastroesophageal reflux symptoms during, 403